| Product | Code | Price | ||
|---|---|---|---|---|
| Cetuximab (anti-EGFR) | A2000 5mg | 5mg |
€ 838,01 | Nous contacter |
| Cetuximab (anti-EGFR) | A2000 1mg | 1mg |
€ 280,14 | Nous contacter |
| Ipilimumab (anti-CTLA-4) | A2001 5mg | 5mg |
€ 2.369,12 | Nous contacter |
| Ipilimumab (anti-CTLA-4) | A2001 20mg | 20mg |
€ 6.632,80 | Nous contacter |
| Ipilimumab (anti-CTLA-4) | A2001 1mg | 1mg |
€ 790,91 | Nous contacter |
| Nivolumab (anti-PD-1) | A2002 5mg | 5mg |
€ 838,01 | Nous contacter |
| Ramucirumab (anti-VEGFR2) | A2003 5mg | 5mg |
€ 838,01 | Nous contacter |
| Atezolizumab (anti-PD-L1) | A2004 5mg | 5mg |
€ 838,01 | Nous contacter |
| Atezolizumab (anti-PD-L1) | A2004 25mg | 25mg |
€ 2.514,02 | Nous contacter |
| Pembrolizumab (anti-PD-1) | A2005 5mg | 5mg |
€ 838,01 | Nous contacter |
| Bevacizumab (anti-VEGF) | A2006 5mg | 5mg |
€ 838,01 | Nous contacter |
| Bevacizumab (anti-VEGF) | A2006 1mg | 1mg |
€ 280,14 | Nous contacter |
Selleckchem Chemicals
Selleck Chemicals supplies over 120,000 inhibitors used in the study of cell signaling pathways. We actively tracks the latest science so our customers can rely on us to be the leading supplier of the newest inhibitors. Selleck's Bioactive Screening Libraries consist of over 8,000 small molecules with validated biological and pharmacological activities. The safety and effectiveness of these molecules has been demonstrated through preclinical and clinical research and many of them are FDA-approved compounds.
More information? Contact Us by e-mail info@divbio.fr